The AIR® Inhaled Insulin System: System components and pharmacokinetic/glucodynamic data

Diabetes Technology and Therapeutics

Volumn 9, Issue SUPPL. 1, 2007, Pages

  Muchmore, Douglas B ^a   Silverman, Bernard ^b   De La Peña, Amparo ^a   Tobian, Janet ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ALKERMES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; DRUG DERIVATIVE; INSULIN LISPRO;

CONFERENCE PAPER; DIABETES MELLITUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRY POWDER; GLYCEMIC CONTROL; HUMAN; INHALER; INSULIN TREATMENT; PRIORITY JOURNAL; AEROSOL; ARTICLE; DRUG EFFECT; EQUIPMENT DESIGN; GLUCOSE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; NEBULIZER;

ADMINISTRATION, INHALATION; AEROSOLS; BLOOD GLUCOSE; EQUIPMENT DESIGN; HUMANS; INSULIN; NEBULIZERS AND VAPORIZERS;

EID: 34250724881     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2007.0218     Document Type: Conference Paper

References (19)

1. International Diabetes Federation, http://www.idf.org/home/index.cfm? unode=7F22F450-B1ED-43BB-A57C-B975D16A812D (accessed March 3, 2007).
2. Cramer JA, Pugh MJ: The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care 2005;28:78-83.
3. Saaddine JB, Cadwell B, Gregg EW, Engelgau M, Vinicor F, Imperatore G, Narayan KMV: Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006;144: 465-474.
4. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO: Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20.
5. Hayes RP, Muchmore D, Schmitke J: Effect of inhaled insulin on patient-reported outcomes and treatment preference in patients with type 1 diabetes. Curr Med Res Opin 2007;23:435-442.
6. Freemantle N, Strack TR: Will availability of inhaled human insulin (Exubera®) improve management of type 2 diabetes? The design of the Real World trial. Trials 2006;7:25. doi:10.1186/1745-6215-7-25.
7. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R: Large porous particles for pulmonary drug delivery. Science 1997;276:1868-1871.
8. Patton JS: Pulmonary delivery of insulin. Curr Med Res Opin 2006;22(Suppl):S5-S11.
9. DeLong M, Wright J, Dawson M, Meyer T, Sommerer K, Dunbar C: Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. J Aerosol Med 2005;18:452-459.
10. Rosenstock J, Nakano M, Silverman BL, Sun B, de la Peña A, Suri A, Muchmore DB: Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HUP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures. Diabetes Technol Ther 2007;9:80-88.
11. Rave KM, Nosek L, de la Peña A, Seger M, Ernest CS II, Heinemann L, Batycky R, Muchmore DB: Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005;28:2400-2405.
12. Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Peña A, Muchmore DB: Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006;49:891-899.
13. Ellis SL, Gemperline KA, Garg S: Review of phase 2 studies utilizing the AIR® particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol Ther 2007; 9(Suppl 1):S-48-S-56.
14. Nakano M, Irie S, Zhang L, Yeo KP, Muchmore DB: Interchangeability between three 2U and one 6U human insulin inhalation powder (HUP) capsules [abstract]. Diabetes 2006;55(Suppl 1):A100.
15. de la Peña A, Irie S, Nakano M, Zhang L, Yuen E, Yeo KP, Muchmore D: Dose interchangeability between human insulin inhalation powder (HIIP) 2U- and 6U-equivalent capsules [abstract]. Diabetologia 2006; 49(Suppl 1):617.
16. Rave K, Hausmann M, de la Peña A, Zhang L, Tibaldi FS, Silverman BL, Heinemann L, Muchmore DB: Pharmacokinetics (PK) and glucodynamics (GD) of human insulin inhalation powder (HIIP) in subjects with chronic obstructive pulmonary disease (COPD). Diabetes 2006;55(Suppl 1):A26.
17. Rave K, de la Peña A, Tibaldi FS, Zhang L, Silverman BL, Heinemann L, Hausmann M, Muchmore DB: Human insulin inhalation powder (HIIP) in subjects with chronic obstructive pulmonary disease (COPD): pharmacokinetic (PK) and glucodynamic (GD) responses [abstract]. Diabetologia 2006;49(Suppl 1):117.
18. Gern J, Stone C, Nakano M, Muchmore DB, Tibaldi F, Suri A, Soon D, Busse W: The effect of symptomatic upper respiratory infection on the pharmacokinetics of human insulin inhalation powder (HIIP) in healthy nondiabetic subjects [abstract]. Proc Am Thorac Society 2006;3:A706.
19. Nakano M, Gern J, Stone C, Tibaldi F, de la PeÒa A, Suri A, Soon D, Muchmore D: Can the human insulin inhalation powder (HIIP) delivery system be used during an upper respiratory infection (URI)? The effect of URI on the pharmacokinetics (PK) and glucodynamics (GD) of HIIP in healthy subjects [abstract]. Diabetologia 2006;49(Suppl 1):617.